Last week a Florida federal jury returned a unanimous verdict in favor of defendant Novartis Pharmaceuticals, rejecting the claim that Novartis' drugs Aredia® and Zometa® caused plaintiff's osteonecrosis of the jaw (ONJ). Aredia® and Zometa® are biphosphonate drugs used to treat cancer patients suffering from metastases to bone. Plaintiff Dopson-Troutt alleged she developed ONJ as a result of taking Aredia® and Zometa® after breast cancer metastasized to her bones. More cases involving Aredia® and Zometa® and ONJ claims are still pending as part of a Multidistrict Litigation (MDL) in a federal court in Tennessee and as part of centralized state court proceedings in New Jersey.
[1] Dopson-Troutt et al v. Novartis Pharmaceuticals Corporation (M.D. Fla.) (8:06-cv-01708).
[2] In Re: Aredia® and Zometa® Products Liability Litigation (M.D. Tennessee) (3:06-md-01760).
[3] In re: Zometa/Aredia Litigation (Superior Court of New Jersey, Middlesex County) (Case No. 278).
[1] Dopson-Troutt et al v. Novartis Pharmaceuticals Corporation (M.D. Fla.) (8:06-cv-01708).
[2] In Re: Aredia® and Zometa® Products Liability Litigation (M.D. Tennessee) (3:06-md-01760).
[3] In re: Zometa/Aredia Litigation (Superior Court of New Jersey, Middlesex County) (Case No. 278).
RSS Feed
